Ya‐Mei Hu

机构：Guangzhou University of Chinese Medicine, Oregon Health & Science University, Tongji Hospital, Huazhong University of Science and Technology · ORCID：0000-0002-2575-1770

发表论文 90 篇 · 总被引 529 次 · h-index 12

代表论文

• Combined BET bromodomain and DNMT inhibition targets critical survival pathways in transdifferentiated prostate cancer (2026 · JCI Insight)
• Figure 2 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types (2026)
• Supplementary Figure S8 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types (2026)
• Supplementary Data 3 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types (2026)
• Supplementary Data 5 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types (2026)
• Supplementary Figure S14 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types (2026)